secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eikon Therapeutics, Inc. (EIKN)
CIK:        0001861123
Form:       8-K
Filed at:   2026-08-14T00:44:35+00:00
Accession:  0001193125-26-349936
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eikon Therapeutics updates Q3 2026 corporate presentation; details not disclosed in filing
--------------------------------------------------------------------------------

- Eikon Therapeutics (EIKN) furnished an updated Q3 2026 corporate presentation on August 13, 2026.
- Exhibit 99.1 content is truncated in the filing; no financial, pipeline, or operational specifics are available.
- CFO Alfred Bowie, Ph.D. signed the current report; no other material events are disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/0001193125-26-349936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer